Data / Drug companies / Avenacy, LLC
Avenacy, LLC: 44 products in the FDA NDC directory, labeler code 83634
Avenacy, LLC (labeler code 83634) lists 44 products in the FDA National Drug Code Directory, covering 30 finished drugs by generic name. By type: 44 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 30, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 83634
- Products in commercial distribution
- 44
- Packages
- 58
- Finished drugs by generic name
- 30
- Prescription products
- 44
- Over the counter products
- 0
- Flagged as original packager
- 40 of 40 products that carry the flag
- Started marketing in the last 12 months
- 11
- Products with a marketing end date set
- 3
- Earliest marketing start
- December 18, 2023
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 41 | 93.2% |
| New drug applications (NDA) | 3 | 6.8% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 44 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 18 | 40.9% |
| Injection, powder, for solution | 17 | 38.6% |
| Injection, powder, lyophilized, for solution | 5 | 11.4% |
| Injection, solution, concentrate | 2 | 4.5% |
| Injection, emulsion | 1 | 2.3% |
| Kit | 1 | 2.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Pantoprazole Sodium | 83634-751 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | September 30, 2026 |
| Cisatracurium Besylate | 83634-655 | Injection, solution | Generic drugs (ANDA) | August 15, 2026 |
| Vancomycin Hydrochloride | 83634-116 | Injection, powder, for solution | New drug applications (NDA) | August 15, 2026 |
| Vancomycin Hydrochloride | 83634-115 | Injection, powder, for solution | New drug applications (NDA) | August 15, 2026 |
| Vancomycin Hydrochloride | 83634-114 | Injection, powder, for solution | New drug applications (NDA) | August 15, 2026 |
| Bortezomib | 83634-208 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | May 1, 2026 |
| Norepinephrine bitartrate | 83634-307 | Injection, solution | Generic drugs (ANDA) | February 1, 2026 |
| Cyclophosphamide | 83634-207 | Injection, powder, for solution | Generic drugs (ANDA) | February 1, 2026 |
| Cyclophosphamide | 83634-206 | Injection, powder, for solution | Generic drugs (ANDA) | February 1, 2026 |
| Cyclophosphamide | 83634-205 | Injection, powder, for solution | Generic drugs (ANDA) | February 1, 2026 |
| Lidocaine hydrochloride | 83634-653 | Injection, solution | Generic drugs (ANDA) | December 31, 2025 |
| Diphenhydramine | 83634-781 | Injection, solution | Generic drugs (ANDA) | September 1, 2025 |
| Tranexamic acid in sodium chloride | 83634-403 | Injection, solution | Generic drugs (ANDA) | September 1, 2025 |
| Piperacillin and Tazobactam | 83634-112 | Injection, powder, for solution | Generic drugs (ANDA) | September 1, 2025 |
| Dehydrated Alcohol | 83634-306 | Injection, solution | Generic drugs (ANDA) | July 17, 2025 |
| Lidocaine hydrochloride | 83634-651 | Injection, solution | Generic drugs (ANDA) | July 1, 2025 |
| Propofol | 83634-603 | Injection, emulsion | Generic drugs (ANDA) | March 30, 2025 |
| Doxycycline | 83634-111 | Injection, powder, lyophilized, for solution | Generic drugs (ANDA) | March 1, 2025 |
| Ampicillin and Sulbactam | 83634-110 | Injection, powder, for solution | Generic drugs (ANDA) | February 1, 2025 |
| Ampicillin and Sulbactam | 83634-109 | Injection, powder, for solution | Generic drugs (ANDA) | February 1, 2025 |
| Ampicillin and Sulbactam | 83634-108 | Injection, powder, for solution | Generic drugs (ANDA) | February 1, 2025 |
| Piperacillin and Tazobactam | 83634-106 | Injection, powder, for solution | Generic drugs (ANDA) | February 1, 2025 |
| Piperacillin and Tazobactam | 83634-105 | Injection, powder, for solution | Generic drugs (ANDA) | February 1, 2025 |
| Piperacillin and Tazobactam | 83634-104 | Injection, powder, for solution | Generic drugs (ANDA) | February 1, 2025 |
| Penicillin G Potassium | 83634-103 | Injection, powder, for solution | Generic drugs (ANDA) | February 1, 2025 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.